Long-Term Complete Remission of Refractory Primary Cutaneous Anaplastic Large T Cell Lymphoma Treated with Brentuximab Vedotin: A Case Report
- *Corresponding Author:
- Sabino Ciavarella
MD, PhD Hematology Unit
IRCCS – Istituto Tumori “G. Paolo II”
Viale O. Flacco, 6570125 Bari, Italy Tel: 390805555416
Received date: June 07, 2017; Accepted date: June 26, 2017; Published date: June 27, 2017
Citation: Loseto G, Ciavarella S, Scattone A, Calabrese A, Quinto AM, et al. (2017) Long-Term Complete Remission of Refractory Primary Cutaneous Anaplastic Large T Cell Lymphoma Treated with Brentuximab Vedotin: A Case Report. J Cancer Sci Ther 9:503-504. doi: 10.4172/1948-5956.1000467
Copyright: © 2017 Loseto G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Based on early results from a single phase III trial, Brentuximab Vedotin (BV), a drug-conjugated anti-CD30 monoclonal antibody, is changing the treatment strategy, especially for relapsed/refractory cutaneous anaplastic large cell lymphomas (cALCL) patients with limited therapeutic options. However, despite high response rates registered in this setting, follow-up data about duration of response and long-term toxicity profile are still lacking. Here, we report a case of refractory, advanced stage cALCL in a 78-year old patient with poor prognosis, which showed a dramatic, long-lasting response even to reduced doses of BV as salvage treatment.